Literature DB >> 22691055

Splicing in oncogenesis and tumor suppression.

Daisuke Kaida1, Tilman Schneider-Poetsch, Minoru Yoshida.   

Abstract

Post-transcriptional modifications, such as 5' end capping, 3' end polyadenylation and splicing, are necessary for the precise regulation of gene expression and transcriptome integrity. Therefore, it is not surprising that abnormalities of these post-transcriptional modifications prompt numerous diseases, including cancer. In fact, many studies revealed that misregulation of mRNA processing, especially splicing, are observed in a variety of cancer cells. In this review we describe how changes within RNA splicing regulatory elements or mutations in the processing factors alter the expression of tumor suppressors or oncogenes with pathological consequences. In addition, we show how several small molecules that bind to spliceosomal components and splicing regulators inhibit or modulate splicing activity. These compounds have anticancer activity and further development of small molecule modulators has potential in next generation cancer therapy.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22691055      PMCID: PMC7659361          DOI: 10.1111/j.1349-7006.2012.02356.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  75 in total

Review 1.  Myelodysplastic syndromes: the complexity of stem-cell diseases.

Authors:  Seth J Corey; Mark D Minden; Dwayne L Barber; Hagop Kantarjian; Jean C Y Wang; Aaron D Schimmer
Journal:  Nat Rev Cancer       Date:  2007-02       Impact factor: 60.716

Review 2.  The SR protein family of splicing factors: master regulators of gene expression.

Authors:  Jennifer C Long; Javier F Caceres
Journal:  Biochem J       Date:  2009-01-01       Impact factor: 3.857

Review 3.  The spliceosome: design principles of a dynamic RNP machine.

Authors:  Markus C Wahl; Cindy L Will; Reinhard Lührmann
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

4.  New antitumor substances, FR901463, FR901464 and FR901465. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities.

Authors:  H Nakajima; B Sato; T Fujita; S Takase; H Terano; M Okuhara
Journal:  J Antibiot (Tokyo)       Date:  1996-12       Impact factor: 2.649

5.  Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia.

Authors:  J S Kühl; S Krajewski; G E Durán; J C Reed; B I Sikic
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma.

Authors:  David O Bates; Tai-Gen Cui; Joanne M Doughty; Matthias Winkler; Marto Sugiono; Jacqueline D Shields; Danielle Peat; David Gillatt; Steven J Harper
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

7.  IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC.

Authors:  Madhu Ramaswamy; Elena V Efimova; Osvaldo Martinez; Nirupama U Mulherkar; Surya P Singh; Bellur S Prabhakar
Journal:  Oncogene       Date:  2004-08-12       Impact factor: 9.867

8.  Heterogeneous nuclear ribonucleoprotein K represses the production of pro-apoptotic Bcl-xS splice isoform.

Authors:  Timothée Revil; Jordan Pelletier; Johanne Toutant; Alexandre Cloutier; Benoit Chabot
Journal:  J Biol Chem       Date:  2009-06-11       Impact factor: 5.157

9.  Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas.

Authors:  Clare V Lefave; Massimo Squatrito; Sandra Vorlova; Gina L Rocco; Cameron W Brennan; Eric C Holland; Ying-Xian Pan; Luca Cartegni
Journal:  EMBO J       Date:  2011-09-13       Impact factor: 11.598

10.  Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma.

Authors:  R O Pritchard-Jones; D B A Dunn; Y Qiu; A H R Varey; A Orlando; H Rigby; S J Harper; D O Bates
Journal:  Br J Cancer       Date:  2007-06-26       Impact factor: 7.640

View more
  32 in total

1.  RQN-18690A (18-deoxyherboxidiene) targets SF3b, a spliceosome component, and inhibits angiogenesis.

Authors:  Hideaki Kakeya; Daisuke Kaida; Hiromi Sekiya; Koji Nagai; Minoru Yoshida; Hiroyuki Osada
Journal:  J Antibiot (Tokyo)       Date:  2015-09-09       Impact factor: 2.649

Review 2.  Alterations in the expression and activity of pre-mRNA splicing factors in hepatocarcinogenesis.

Authors:  Carmen Berasain; María Elizalde; Raquel Urtasun; Josefa Castillo; Oihane García-Irigoyen; Iker Uriarte; Maria U Latasa; Jesús Prieto; Matías A Avila
Journal:  Hepat Oncol       Date:  2014-03-20

3.  Integrated molecular analysis of adult T cell leukemia/lymphoma.

Authors:  Keisuke Kataoka; Yasunobu Nagata; Akira Kitanaka; Yuichi Shiraishi; Teppei Shimamura; Jun-Ichirou Yasunaga; Yasushi Totoki; Kenichi Chiba; Aiko Sato-Otsubo; Genta Nagae; Ryohei Ishii; Satsuki Muto; Shinichi Kotani; Yosaku Watatani; June Takeda; Masashi Sanada; Hiroko Tanaka; Hiromichi Suzuki; Yusuke Sato; Yusuke Shiozawa; Tetsuichi Yoshizato; Kenichi Yoshida; Hideki Makishima; Masako Iwanaga; Guangyong Ma; Kisato Nosaka; Masakatsu Hishizawa; Hidehiro Itonaga; Yoshitaka Imaizumi; Wataru Munakata; Hideaki Ogasawara; Toshitaka Sato; Ken Sasai; Kenzo Muramoto; Marina Penova; Takahisa Kawaguchi; Hiromi Nakamura; Natsuko Hama; Kotaro Shide; Yoko Kubuki; Tomonori Hidaka; Takuro Kameda; Tsuyoshi Nakamaki; Ken Ishiyama; Shuichi Miyawaki; Sung-Soo Yoon; Kensei Tobinai; Yasushi Miyazaki; Akifumi Takaori-Kondo; Fumihiko Matsuda; Kengo Takeuchi; Osamu Nureki; Hiroyuki Aburatani; Toshiki Watanabe; Tatsuhiro Shibata; Masao Matsuoka; Satoru Miyano; Kazuya Shimoda; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

4.  Multifunctional RNA processing protein SRm160 induces apoptosis and regulates eye and genital development in Drosophila.

Authors:  Yu-Jie Fan; Aryn H Gittis; François Juge; Chen Qiu; Yong-Zhen Xu; Leonard Rabinow
Journal:  Genetics       Date:  2014-06-06       Impact factor: 4.562

5.  Tumor suppressor properties of the splicing regulatory factor RBM10.

Authors:  Jordi Hernández; Elias Bechara; Doerte Schlesinger; Javier Delgado; Luis Serrano; Juan Valcárcel
Journal:  RNA Biol       Date:  2016       Impact factor: 4.652

6.  The impact of SF3B1 mutations in CLL on the DNA-damage response.

Authors:  G D Te Raa; I A M Derks; V Navrkalova; A Skowronska; P D Moerland; J van Laar; C Oldreive; H Monsuur; M Trbusek; J Malcikova; M Lodén; C H Geisler; J Hüllein; A Jethwa; T Zenz; S Pospisilova; T Stankovic; M H J van Oers; A P Kater; E Eldering
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

7.  Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase.

Authors:  Alessandra S Eustáquio; Jeffrey E Janso; Anokha S Ratnayake; Christopher J O'Donnell; Frank E Koehn
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

Review 8.  Dysregulation of the basal RNA polymerase transcription apparatus in cancer.

Authors:  Megan J Bywater; Richard B Pearson; Grant A McArthur; Ross D Hannan
Journal:  Nat Rev Cancer       Date:  2013-05       Impact factor: 60.716

9.  cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases inhibitor leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer's disease.

Authors:  Xavier Fant; Emilie Durieu; Gaëtan Chicanne; Bernard Payrastre; Diego Sbrissa; Assia Shisheva; Emmanuelle Limanton; François Carreaux; Jean-Pierre Bazureau; Laurent Meijer
Journal:  Mol Pharmacol       Date:  2013-12-23       Impact factor: 4.436

10.  Expression of SRPK1 in gliomas and its role in glioma cell lines viability.

Authors:  Ioanna Sigala; Konstantinos I Tsamis; Anna Gousia; George Alexiou; Spyridon Voulgaris; Thomas Giannakouros; Athanassios P Kyritsis; Eleni Nikolakaki
Journal:  Tumour Biol       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.